# DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease

> **NCT04218656** · PHASE4 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 159 (actual)

## Conditions studied

- Peripheral Artery Disease

## Interventions

- **DRUG:** Rivaroxaban 2.5 Mg Oral Tablet

## Key facts

- **NCT ID:** NCT04218656
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-08
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2022-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04218656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04218656, "DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04218656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*